Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO versus rhIL-11 for thrombocytopenia after CHOP chemotherapy in aggressive lymphoma
ChiCTR1800019725Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin and oprelvekin in Thrombocytopenia and lymphoma (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Platelet count. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietinoprelvekin
03
Conditions
Thrombocytopenialymphoma
Beyond the preview
Go deeper on ChiCTR1800019725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019725.